Aducanumab reduces Aβ plaques in Alzheimer's disease

被引：8
|
作者：
Vaillancourt, David E. [1 ,2 ]
机构：
[1] Univ Florida, Dept Neurol, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA
[2] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA
来源：
MOVEMENT DISORDERS | 2016年 / 31卷 / 11期
关键词：
PARKINSON DISEASE;
D O I：
10.1002/mds.26833
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1631 / 1631
页数：1
相关论文
共 50 条
  • [21] New drugs for Alzheimer's disease: Aducanumab or Donanemab?
    Joodaki, Mehran
    Shirazi, Mona Merati
    Hosseini, Nasrin
    PHYSIOLOGY AND PHARMACOLOGY, 2024, 28 (03): : 219 - 236
  • [22] Aducanumab for the treatment of Alzheimer's disease: a systematic review
    Rahman, Afroza
    Hossen, Md Anwar
    Chowdhury, Mirza Farhana Iqbal
    Bari, Sadia
    Tamanna, Nuzhat
    Sultana, Syeda Salima
    Haque, Sharar Naiarin
    Al Masud, Abdullah
    Saif-Ur-Rahman, K. M.
    PSYCHOGERIATRICS, 2023, 23 (03) : 512 - 522
  • [23] Population Pharmacokinetics of Aducanumab in Patients with Alzheimer's Disease
    Kandadi, Kumar
    Nestorov, Ivan
    von Rosenstiel, Philipp
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S68 - S68
  • [24] Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
    Christopher Janus
    Jacqueline Pearson
    JoAnne McLaurin
    Paul M. Mathews
    Ying Jiang
    Stephen D. Schmidt
    M. Azhar Chishti
    Patrick Horne
    Donna Heslin
    Janet French
    Howard T.J. Mount
    Ralph A. Nixon
    Marc Mercken
    Catherine Bergeron
    Paul E. Fraser
    Peter St George-Hyslop
    David Westaway
    Nature, 2000, 408 : 979 - 982
  • [25] Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
    Janus, C
    Pearson, J
    McLaurin, J
    Mathews, PM
    Jiang, Y
    Schmidt, SD
    Chishti, MA
    Horne, P
    Heslin, D
    French, J
    Mount, HTJ
    Nixon, RA
    Mercken, M
    Bergeron, C
    Fraser, PE
    St George-Hyslop, P
    Westaway, D
    NATURE, 2000, 408 (6815) : 979 - 982
  • [26] Aducanumab for Alzheimer's disease: expediting approval and delaying science
    Salinas, Rodrigo A.
    BMJ EVIDENCE-BASED MEDICINE, 2021, 26 (05) : 214 - 215
  • [27] Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective
    Dunn, Billy
    Stein, Peter
    Cavazzoni, Patrizia
    JAMA INTERNAL MEDICINE, 2021, 181 (10) : 1276 - 1278
  • [28] Regulatory decisions diverge over aducanumab for Alzheimer's disease
    Lythgoe, Mark P.
    Jenei, Kristina
    Prasad, Vinay
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [29] Role of Aducanumab in the Treatment of Alzheimer?s Disease: Challenges and Opportunities
    Vaz, Miguel
    Silva, Vitor
    Monteiro, Cristina
    Silvestre, Samuel
    CLINICAL INTERVENTIONS IN AGING, 2022, 17 : 797 - 810
  • [30] Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
    Heidebrink, Judith L.
    Paulson, Henry L.
    ANNUAL REVIEW OF MEDICINE, 2024, 75 : 99 - 111
12345